Atezolizumab,Bevacizumab
Roche
['hcc', 'atezo']
fantastic news for for hcc. adjuvant atezo/bev met its primary end point of recurrence free survival. will there be a new standard of care after liver cancer resection? can't wait for final results!
#aacr23
#asco23 
Reimagining cancer clinical trials. 
Foodie, family guy, digital health.
FCOI: https://t.co/CtEt9hUmRB